Human malignant glioma cell lines are sensitive to low radiation doses

International Journal of Cancer

Volumn 105, Issue 1, 2003, Pages 33-40

  Beauchesne, Patrick D ^a,b   Bertrand, Suzanne ^b   Branche, Robert ^b   Linke, Steven P ^c   Revel, Roland ^b   Dore, Jean François ^b   Pedeux, Rémy M ^b,c  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b INSERM   (France)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Glioma; Low dose hypersensitivity; Radiotherapy; Ultrafractionation; Xenograft

Indexed keywords

ETOPOSIDE;

ARTICLE; CANCER RADIOTHERAPY; CELL KILLING; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; TUMOR GROWTH; X IRRADIATION; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETOPOSIDE; FEMALE; GLIOMA; HUMANS; MICE; NEOPLASM TRANSPLANTATION; RADIATION TOLERANCE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037457667     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11033     Document Type: Article

References (53)

1. Black P. Brain tumors (first part). N Engl J Med 1991;21:1471-6.
2. Black P. Brain tumors (second part). N Engl J Med 1991;22:1555-64.
3. Fine HA, Dear KB, Loeffler JS, Black P, Canellos GP. Meta-analysis of radiotherapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97.
4. Kleihues P, Ohgaki H. Primary and secondary glioblastoms: from concept to clinical diagnosis. Neurooncology 1999;1:44-51.
5. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-23.
6. James CD, Olson JJ. Molecular genetics and molecular biology advances in brain tumors. Curr Opin Oncol 1996;8:188-95.
7. Joiner MC, Denekamp J, Maughan RL. The use of "top-up" experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol 1986;49:565-80.
8. Lambin P, Malaise EP, Joiner MC. The effect of very low radiation doses on the human bladder carcinoma cell line RT112. Radiother Oncol 1994;32:63-72.
9. Lambin P, Malaise EP, Joiner MC. Might intrinsic radioresistance of human tumor cells be induced by radiation. Int J Radiat Biol 1996;69:279-90.
10. Marples B, Lambin P, Skov KA, Joiner MC. Low dose hyperradiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol 1997;71:721-35.
11. Short S, Mitchell S, Boulton P, Woodcock M, Joiner MC. The response of human glioma cell lines to low-dose radiation exposure. Int J Radiat Biol 1999;75:1341-8.
12. Beauchesne P, Bertrand S, N'guyen MJ, Christianson T, Dore JF, Mornex F, Bonner JA. Etoposide sensitivity of radioresistant human glioma cell lines. Cancer Chemother Pharmacol 1998;41:93-7.
13. Jacubovich R, Cabrillat H, Gerlier D, Bailly M, Dore JF. Tumorigenic phenotypes of human melanoma cell lines in nude mice determined by active antitumor mechanism. Br J Cancer 1985;51:335-45.
14. Gauchez AS, Riondel J, Fernandes-Carlos T, Jacrot M, Guiraud P, Coudray C, Calop J, Favier A. Effect of oestrone on the natural killer (NK) cell activity, antioxidant status and tumor growth in athymic mice xenografted with human tumors. Anticancer Res 1996;16:853-60.
15. Puck TT, Markus PI. Action of X-rays on mammalian cells. J Exp Med 1956;103:653-66.
16. Hall EJ. Radiobiology for the radiologist, 2nd ed. Hargestown: Harper and Row, 1978.
17. Longo JA, Nevaldine B, Longo SL, Winfield JA, Hahn PJ. An assay for quantifying DNA double-strand break repair that is suitable for small numbers of unlabeled cells. Radiat Res 1997;147:35-40.
18. Thames HD. Effect-independent measures of tissue responses to fractionated irradiation. Int J Radiat Biol Med 1984;45:1-10.
19. Fowler JF. "Fading times" required for apparently complete repair in irradiated tissues assuming the linear quadratic model of dose response. Int J Radiat Biol 1986;50:601-7.
20. Nguyen TD, Demange L, Froissart D, Panis X, Loirette M. Rapid hyperfractionated radiotherapy. Clinical results in 178 advanced squamous cell carcinomas of the head and neck. Cancer 1985;56:16-9.
21. Short SC, Kelly J, Mayes CR, Woodcock M, Joiner MC. Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol 2001;77:655-64.
22. Beauchesne P, Bertrand S, Revel R, Pialat J, Brunon J, Mornex F, Dore JF. Development of an intracerebral glioma model in whole body irradiated hairless rats. Anticancer Res 2000;20:703-6.
23. Beauchesne P, Soler C, Rusch P, Fotso MJ, Duthel R, Schmitt T, Brunon J. Phase II study of a radiotherapy/etoposide combination for patients with newly malignant gliomas. Cancer Chemother Pharmacol 1999;44:210-6.
24. Taghian A, Suit H, Pardo F, Gioioso D, Tomkinson K, DuBois W, Gerweck L. In vitro intrinsic radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1992;3:55-62.
25. Taghian A, Ramsay J, Allalunis-Turner J, Budach W, Gioioso D, Pardo F, Okunieff P, Bleehen N, Urtasun R, Suit H. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1993;25:243-9.
26. Joiner MC, Marples B, Lambin P, Short SC, Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001;49:379-89.
27. Wouters BG, Sky AM, Skarsgard LD. Low dose hypersensitivity and increased radioresistance in a panel of human tumor cell lines with different radiosensitivity. Radiat Res 1996;146:399-413.
28. Short S, Mayes C, Woodcock M, Johns H, Joiner MC. Low dose hypersensitivity in the T98G human glioblastoma cell line. Int J Radiat Biol 1999;75:847-55.
29. Dionet C, Tchirkov A, Alard JP, Arnold J, Dhermain J, Rapp M, Bodez V, Tamain JC, Monbel I, Malet P, Kwiatkowski F, Donnarieix D, et al. Effects of low-dose neutrons applied at reduced dose rate on human melanoma cells. Radiat Res 2000;154:406-11.
30. Sneed PK, Gutin PH, Larson DA, Malec MK, Phillips TL, Prados MD, Scharfen CO, Weaver KA, Wara WM. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994;29:719-27.
31. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
32. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
33. 60Co gamma rays on human tumor cells in vitro. Radiat Res 2002;158:311-8.
34. Withers HR, Thames HD, Peters LJ. Differences in fractionation response of acutely and late-responding tissues. In: Karcher KH. Kogelnick HD, Reinartz G, eds. Progress in radio-oncology. vol. II. New York: Raven Press, 1982. p. 287-94.
35. Thames HD. Early fractionation methods and the origins of the NSD concept. Acta Oncol 1988;27:89-103.
36. Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, et al. Phase III trial of accelerated hyperfractionation with or without difluoromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;49: 71-7.
37. Murray KJ, Nelson DF, Scott C, Fischbach AJ, Porter A, Farnan N, Curran WJ. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiat Oncol Biol Phys 1995;31:453-9.
38. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995;6:325-41.
39. Steel GG, Pecckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.
40. Giocanti N, Hennequin C, Balosso J, Mahler M, Favaudon V. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 1993;53:2105-11.
41. Minehan KJ, Bonner JA. The interaction of etoposide with radiation: variation in cytoxicity with the sequence of treatment. Life Sci 1993;53:337-42.
42. Tirelli U, D'Incalci M, Canetta R, Tumolo S, Franchin G, Veronesi A, Galligioni E, Trovo MG, Rossi C, Grigoletto E. Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol 1984;2:432-7.
43. Vokes EE. Interactions of chemotherapy and radiation. Semin Oncol 1993;20:70-9.
44. Weiss J, Schwecheimer K, Cavenee WK, Herlyn M, Arden KC. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 1993;54:693-9.
45. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, Nanus DM. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 1994;4:35-45.
46. Montano X, Shamsher M, Whitehead P, Dawson K, Newton J. Analysis of p53 in human cutaneous melanoma cell lines. Oncogene 1994;9:1455-9.
47. Russell NS, Bartelink H. Radiotherapy: the last 25 years. Cancer Treat Rev 1999;25:365-76.
48. Mehta MP, Tome WA, Olivera GH. Radiotherapy for brain tumors. Curr Oncol Rep 2000;2:438-44.
49. Dische S, Saunders MI. Continuous, hyperfractionated, accelerated radiotherapy (CHART). Br J Cancer 1989;59:325-6.
50. Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, Kovnar E, Burger P, Sanford RA, Kepner J, Friedman H, Kun LE. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999;43:959-64.
51. Mendenhall WM, Amdur RJ, Siemann DW, Parsons JT. Altered fractionation in definitive irradiation of squamous cell carcinoma of the head and neck. Curr Opin Oncol 2000;12:207-14.
52. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-5.
53. Hasegawa M, Niibe H, Mitsuhashi N, Yamakawa M, Kato S, Furuta M, Kazumoto T, Hayakawa K, Nakazato Y. Hyperfractionated and hypofractionated radiation therapy for human malignant glioma xenograft in nude mice. Jpn J Cancer Res 1995;86:879-84.